Working Together Making a Difference
The Liver Institute in Tucson Arizona has been designed to offer a comprehensive multidisciplinary approach to the diagnosis and management of liver disease.
Broad spectrum liver disease evaluation and management both as outpatient and inpatient
Advanced liver disease care: Liver failure management
Pre-liver transplantation: Evaluation and bridge to transplantation
Post liver transplantation care: Focused on immunosuppression and prevention & management of long term complication
Multidisciplinary team approach to care of liver cancers with intensive focus on cure of cancer
Multidisciplinary team approach to alcohol and non-alcohol liver disease with intensive focus on nutrition management, lifestyle intervention and documented sobriety program
Hepatitis C and B evaluation and management with intention of cure
Utilization of customized EMR to provide and assess quality based care especially focused on preventive care with highest compliance
St. Joseph Hospital, Tucson
St. Mary Hospital
According to healthline, liver disease is responsible for about 1.5 percent of deaths in the United States each year; about 40,265 per year.
Liver Disease Distribution
Below is a summary of our patient distribution at the Liver Institute categorized into the five categories: Viral Hepatitis; including Hep B and Hep C, Autoimmune liver disease; including Autoimmune hepatitis and Primary Biliary Cholangitis (PBC) and Abnormal LFT, Fatty Liver Disease; including NAFLD and non-alcoholic steatohepatitis (NASH) and Alcohol liver disease including Alcohol Cirrhosis.
From our total number of patients, approximately 54% also developed cirrhosis; a chronic late-stage scarring (fibrosis score of F4) of the liver tissue, possibly as a result of other liver diseases. When Cirrhosis causes notable symptoms, the diagnosis is labeled as decompensated cirrhosis. If it does not cause any symptoms then it’s compensated cirrhosis. Some of the complications and symptoms include ascites (fluid accumulation in the abdominal area), fatigue, edema, anemia, etc. This data from our patient is summarized in the chart below.
One of the other possible complication of chronic liver disease and cirrhosis is Hepatocellular Carcinoma (HCC), the most common type of primary liver cancer. At the Liver Institute patients are frequently monitored for signs or symptoms of HCC as well as through blood tests. The chart below shows the number of patients that were diagnosed with HCC over the past three years.
Decompensation increases Mortality Risk
The following graphs shows hazard (risk of death) and survival probability over time for patients with decompensated cirrhosis (green) compared to other liver disease patients (blue). The data below reveals a gradual and significant increase in delayed mortality risk of up to 32% compared to about 1% in other patients as well as a survival probability of about 85% in decompensated cirrhosis patients as compared to almost 100% in other patients.